# AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma

> **NCT05602363** · PHASE1 · RECRUITING · sponsor: **Carna Biosciences, Inc.** · enrollment: 120 (estimated)

## Conditions studied

- B-cell Malignancy
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Waldenstrom Macroglobulinemia
- Mantle Cell Lymphoma
- Marginal Zone Lymphoma
- Follicular Lymphoma
- Non-Hodgkin Lymphoma

## Interventions

- **DRUG:** Docirbrutinib

## Key facts

- **NCT ID:** NCT05602363
- **Lead sponsor:** Carna Biosciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-08-01
- **Primary completion:** 2027-09
- **Final completion:** 2027-09
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2025-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05602363

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05602363, "AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT05602363. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*